CONCLUSION. These data suggest that a gene signature of IL-17 airway epithelial response distinguishes a biologically, radiographically, and clinically distinct COPD subgroup that may benefit from personalized therapy. The gene discussed is IL17A; the disease is chronic obstructive pulmonary disease.